TNFRSF8-eiwit (C-His, mens)

TNFRSF8

CD30, D1S166E, Ki-1

C-His

< 1.0 EU per μg of the protein as determined by the LAL method

≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.

1.Immobilized Human CD30L hFc (Cat: 10040-H01H) at 2 μg/mL (100 μL/well) can bind Human CD30/TNFRSF8 His (Cat: 10777-H08H), the EC50 of Human CD30/TNFRSF8 His is 30-180 ng/mL (QC tested) . 2.Immobilized Recombinant Human CD30 / TNFRSF8 Protein (His Tag) (Cat: 10777-H08H) at 1 μg/mL (100 μL/well) can bind Anti-CD30 (Research grade Brentuximab biosimilar), the EC50 is 1-8 ng/mL (Routinely tested) . 3.Immobilized Anti-CD30 (Research Grade Brentuximab biosimilar) at 2 μg/mL (100 μL/well) can bind Recombinant Human CD30 / TNFRSF8 Protein (His Tag) (Cat: 10777-H08H), the EC50 is 3.1 ng/mL (Routinely tested) .

Met1-Lys379

The secreted recombinant human TNFRSF8 consists of 372 amino acids and has a predicted molecular mass of 40 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhTNFRSF8 is approximately 75-90 kDa due to glycosylation.

Human